Patents Assigned to Institute for Cancer Research
  • Enhanced immune cell receptor sequencing methods
    Patent number: 11319590
    Abstract: Disclosed are methods for sequencing immune cell receptor repertoires from immune cell populations, the methods comprising isolating RNA from immune cells, generating cDNA from the RNA, ligating adapter sequences to the cDNA, and sequencing the cDNA. Also provided are kits containing primer mixtures for the sequencing of immune cell receptor repertoires.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: May 3, 2022
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventor: Raphael Genolet
  • Bisulfite-free, base-resolution identification of cytosine modifications
    Patent number: 11306355
    Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: April 19, 2022
    Assignee: Ludwig Institute for Cancer Research Ltd
    Inventors: Chunxiao Song, Yibin Liu
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 11267889
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 8, 2022
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
  • Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance
    Patent number: 11261225
    Abstract: Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: March 1, 2022
    Assignee: INSTITUTE FOR CANCER RESEARCH
    Inventors: Roland L. Dunbrack, Jared Adolf-Bryfogle, Gregory P. Adams, Matthew K. Robinson
  • 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
    Patent number: 11253521
    Abstract: Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1) and/or GEN1.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 22, 2022
    Assignee: Ludwig Institute for Cancer Research Ltd
    Inventors: Timothy Gahman, Andrew Shiau, Richard Kolodner
  • HUMAN CHORIONIC GONADOTROPIN VARIANT PEPTIDES AND TREATMENT OF BREAST CANCER
    Publication number: 20220041679
    Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.
    Type: Application
    Filed: October 15, 2018
    Publication date: February 10, 2022
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventors: Jose Russo, Yanrong Su, Julia Santucci Pereira Del Buono, Mark Andrake
  • Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
    Patent number: 11242351
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 8, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases
    Patent number: 11240996
    Abstract: Mice comprising a transgene encoding a peptide (iBox) inhibitor of Group B p21-activated kinase are provided. Also provided are cells, tissue, and organs obtained from such transgenic mice. Also provided are methods for producing mice comprising an iBox-encoding transgene.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: February 8, 2022
    Assignee: Institute For Cancer Research
    Inventors: Jonathan Chernoff, Hoi Yee Chow
  • Isoxazole compounds as inhibitors of heat shock proteins
    Patent number: 11234987
    Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: February 1, 2022
    Assignees: Cancer Research Technology Limited, The Institute of Cancer Research, Vernalis (R&D) Limited
    Inventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
  • Anti-GARP protein
    Patent number: 11230603
    Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: January 25, 2022
    Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, UNIVERSITÉ CATHOLIQUE DE LOUVAIN, argenx BVBA
    Inventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld, Sebastian van der Woning, Michael Saunders, Hans De Haard, Gitte De Boeck
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20220017600
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: February 25, 2021
    Publication date: January 20, 2022
    Applicants: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • Methods and devices for predicting anthracycline treatment efficacy
    Patent number: 11214836
    Abstract: The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, RFC4, and MSH6, collectively referred to as CIN4. Patients that have a low CIN4 score benefit from anthracycline treatment compared patients with a high CIN4 score.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: January 4, 2022
    Assignee: Ontario Institute for Cancer Research
    Inventors: Melanie Spears, John Bartlett, Fouad Yousif, Paul Boutros
  • Methods for treating GI syndrome and graft versus host disease
    Patent number: 11207329
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 28, 2021
    Assignees: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Methods and medical uses
    Patent number: 11207321
    Abstract: The invention described herein provides a method for the treatment of an oestrogen receptor positive breast cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a compound capable of inhibiting MPS1, wherein: (i) said subject has previously been treated with a CDK4/6 inhibitor; and/or (ii) said breast cancer is resistant to treatment with a CDK4/6 inhibitor.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 28, 2021
    Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Breast Cancer Now
    Inventors: Lesley-Ann Martin, Joanna Nikitorwicz-Buniak
  • Compounds for repressing cancer cell growth
    Patent number: 11203598
    Abstract: The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth. In particular, the compounds comprise Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen or a haloalkyl group; and each R2, R3, R4, R5, R6, and R7 is, independently, hydrogen, halogen, hydroxyl, cyano, alkyl, alkenyl, alkoxy, substituted or unsubstituted aryl, heteroaryl, phosphate, phosphoramidate, amine, alkylamino, acylamino, aminoalkoxy, or alkylthio.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: December 21, 2021
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Shengliang Zhang, Liz J. Hernandez Borrero
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20210388104
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: January 4, 2021
    Publication date: December 16, 2021
    Applicants: Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • Azolium salts for treatment of non-muscle invasive bladder cancer
    Patent number: 11197873
    Abstract: The present invention provides pharmaceutical compounds for the treatment of high-grade superficial bladder cancer in patent in need thereof. Further described are compositions of azolium salts for use in such treatment.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: December 14, 2021
    Assignees: The University of Akron, The Institute for Cancer Research
    Inventors: Wiley Jay Youngs, Philip H. Abbosh, Michael Lee Stromyer, Marie Renee Southerland, Uttam Satyal, David Joseph Weader
  • Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders
    Patent number: 11192880
    Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: December 7, 2021
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Methvin Isaac, Anh My Chau
  • Methods of diagnosing and treating cancer targeting extrachromosomal DNA
    Patent number: 11193164
    Abstract: Provided herein are, inter alia, methods and compositions to detect, monitor and treat cancer, wherein the cancer includes amplified extrachromosomal oncogenes. The methods are useful for personalized treatment and exploit differential expression of amplified extrachromosomal oncogenes in cancer cells versus healthy cells.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: December 7, 2021
    Assignees: The Regents of the University of California, Ludwig Institute for Cancer Research Ltd
    Inventors: Paul Mischel, Prashant Mali, Vineet Bafna, Kristen Turner, Viraj Deshpande, Doruk Beyter
  • Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
    Patent number: 11180812
    Abstract: The present invention is directed to methods of diagnosing, prognosing, and monitoring cancer in a subject. These methods involves selecting a subject having cancer, and obtaining, from the selected subject, a sample containing exosomal DNA. The presence or absence of one or more mutations in BRAF and/or EGFR is detected in the exosomal DNA sample from the subject, and a diagnosis and/or prognosis of the cancer is given based on the detection of the one or more mutations in BRAF and/or EGFR. The present invention further relates to methods of treating a subject having cancer and/or monitoring a subject response to therapy based on the detection of one or more mutations in BRAF and/or EGFR in the exosomal DNA sample.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: November 23, 2021
    Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Jacqueline Bromberg